| In Vivo |
AMG-8718 (compound 42) (10 mg/kg; p.o.)shows significantly decreases Aβ40 levels in the CSF and brain[1]. AMG-8718 (i.v. for 2 mg/kg or p.o. for 5 mg/kg) shows good bioavailability of 70%, 96%,101% for rats, beagle dog, monkey, respectively[1]. AMG-8718 (30 mg/kg for; p.o.) dose-dependent decreases in both CSF and brain Aβ levels at 4 h time points with 50% Aβ reduction (EC50) values of 18 and 67 nM for CSF and brain respectively in rats[1]. AMG-8718 (2.5, 8, 16 mg/kg; i.v.; a series of three 30 min infusions) shows high unbound plasma concentrations with 0.298, 1.70, 3.62 µM at the end of each infusion in chloralose-anesthetized dogs[1]. Pharmacokinetic Parameters ofAMG-8718 in rats, beagle dog, cynomolgus monkey[1]. species Cl (L/h/kg) Vdss(L/kg) t1/2(h) Cmax (µM) tmax(h) % F plasma protein binding (Fu) i.v. p.o. rat 0.33 1.1 4.8 3.8 1.7 70 0.013 beagle dog 0.26 1.6 5.2 8.1 1.0 96 0.038 monkey 0.61 2.2 7.7 6.1 1.7 101 0.0542 mg/kg i.v.; rats (DMSO), dog (1% Tween80/2% HMPC/97% water at pH = 4), cynomolgus monkey (25% HBC/75% water at pH = 4); 5 mg/kg p.o. (1% Tween80/2% HMPC/97% water at pH = 2)[1]. Animal Model: Male Sprague-Dawley rats[1] Dosage: 10 mg/kg Administration: Oral gavage Result: Significantly decreased Aβ40 levels in the CSF at the 4 h time point at 69%, produced a robust response in the brain with 48% reduction of Aβ40 levels. Animal Model: Rats, beagle dog, monkey[1] Dosage: 2, 5 mg/kg Administration: I.v. for 2 mg/kg or p.o. for 5 mg/kg Result: Showed moderate total clearance, moderate Vdss, and half-lives of ca. 5-8 h across all three species, and bioavailability was high (70–101%). Animal Model: Rats[1] Dosage: 30 mg/kg Administration: P.o. Result: Demonstrated dose-dependent decreases in both CSF and brain Aβ levels at 4 h and 8 h time points.
|
